Puig Brands Shares Fall 3.5% to €16.88 After €1.2 Billion ISDIN Deal

Spanish beauty group Puig Brands saw its shares fall 3.5% to €16.88 on Tuesday after unveiling a €1.2 billion ($1.41 billion) agreement to acquire Esteve’s remaining 50% stake in dermatology-focused skincare brand ISDIN, giving it full ownership. The market reacted negatively to the deal’s financing structure and near-term balance-sheet impact, as reported by Reuters and other market sources, even as the company highlighted the strategic boost to its dermocosmetics portfolio.

€1.2bn ISDIN Buyout: €900m Upfront, €300m Deferred, Leverage Cap at 2x

Puig Brands agreed to purchase Esteve’s 50% stake in ISDIN for a total of €1.2 billion. The structure involves an immediate cash payment of €900 million upon closing—expected by the end of the first quarter of 2027, subject to regulatory approvals—and a fixed, interest-free deferred payment of €300 million due in the first quarter of 2029.

The transaction will be funded through a mix of internal resources and new debt. Puig stated that its net debt-to-adjusted EBITDA ratio will not exceed 2.0 times after the deal, in line with its existing medium-term guidance. The full acquisition values ISDIN at approximately €2.4 billion, or about 3.7 times its 2025 sales of roughly €648–650 million (with profits around €60 million). Full ownership will allow Puig to consolidate 100% of ISDIN’s results and accelerate growth in the higher-margin dermocosmetics segment.

Shares Open at Session Low as Debt Burden Outweighs Strategic Upside

Investors focused primarily on the near-term financial strain rather than the long-term strategic rationale. Shares opened at the session low and declined around 3.4–3.5% to the €16.88–€16.89 area, erasing the previous day’s 0.81% gain that left the stock at €17.49. The debt-reliant financing is expected to lift net leverage, reducing financial flexibility at a time when the premium beauty sector faces softer consumer demand and normalizing fragrance growth. A broader risk-off tone in U.S. and European equity markets provided no offsetting support, while peers such as L’Oréal also traded cautiously amid sector-wide M&A concerns.

50-Year Partnership Ends as Puig Targets Dermocosmetics Growth Post-Estée Lauder Talks

Puig and the Esteve family co-founded ISDIN 50 years ago, combining pharmaceutical expertise with beauty innovation. The brand has grown into an international player in dermatology-linked skincare and photoprotection. Taking full control marks the end of that long partnership and comes just months after Puig’s merger talks with Estée Lauder collapsed in May 2026.

Puig, which listed in May 2024 at €24.50, has been expanding its skincare footprint (including brands such as Uriage, Apivita and Dr. Barbara Sturm) as fragrance demand normalizes and Middle East travel retail remains under pressure. ISDIN’s roughly €650 million in 2025 sales will more than double Puig’s dermocosmetics exposure once fully consolidated. Management described the move as a strategic priority to strengthen science-backed skincare capabilities and support the next phase of growth.

Closing Targeted for Q1 2027; Focus on Leverage and Regulatory Clearance

The deal is expected to close by the end of the first quarter of 2027, pending competition and regulatory approvals. Until then, ISDIN will continue to operate under its existing governance. Investors will closely monitor Puig’s leverage trajectory as the €900 million payment approaches, the integration of ISDIN’s full results, and any updates on dermocosmetics growth rates. Successful execution within the 2x net debt/EBITDA ceiling, combined with stronger skincare contribution, could help restore confidence; any slippage on leverage or slower-than-expected synergies may keep pressure on the shares.